Last reviewed · How we verify
Transfusion graft
Transfusion graft is a Small molecule drug developed by Association for Training, Education, and Research in Hematology, Immunology, and Transplantation. It is currently in Phase 1 development.
Transfusion graft is associated with conditions such as leukemia, lymphoma, coronary artery disease, and coronary artery bypass grafting. The treatment involves interventions like observational transplant analysis, Rituximab, and 111In Ibritumomab, and is related to a drug that acts as an erythropoietin receptor agonist.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Transfusion graft |
|---|---|
| Sponsor | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
- Re-infusion of Unwashed Shed Blood During Off-pump Surgery (NA)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease (PHASE2)
- Siplizumab for Sickle Cell Disease Transplant (PHASE1, PHASE2)
- Comparison of Wound Healing for Diabetic Carbuncle Treated With Incision and Drainage Technique Using Cruciate Incision vs Saucerization Technique Both Followed by Vacuum Assisted Closure. (NA)
- Restrictive Fluid Management In Liver Transplantation (REFIL) (NA)
- Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transfusion graft CI brief — competitive landscape report
- Transfusion graft updates RSS · CI watch RSS
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation portfolio CI
Frequently asked questions about Transfusion graft
What is Transfusion graft?
Who makes Transfusion graft?
What development phase is Transfusion graft in?
Related
- Manufacturer: Association for Training, Education, and Research in Hematology, Immunology, and Transplantation — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing